GeneXpert—A Game-Changer for Tuberculosis Control?

Carlton Evans considers whether the new tuberculosis diagnostic test, GeneXpert, is the solution for TB control that it's said to be.

[1]  Michael L Wilson.  Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  P. Daley,et al.  Does solid culture for tuberculosis influence clinical decision making in India? , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  A. R. Escombe,et al.  Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. , 2006, The American journal of tropical medicine and hygiene.

[4]  C. Dye,et al.  Trends in tuberculosis incidence and their determinants in 134 countries. , 2009, Bulletin of the World Health Organization.

[5]  S. Ottmani.  Respiratory care in primary care services: a survey in 9 countries , 2004 .

[6]  Irene Ayakaka,et al.  Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology , 2009, Journal of Clinical Microbiology.

[7]  Madhukar Pai,et al.  Tuberculosis diagnosis--time for a game change. , 2010, The New England journal of medicine.

[8]  Donna Neuberg,et al.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. , 2003, The New England journal of medicine.

[9]  J. Kop,et al.  Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay , 2010, Journal of Clinical Microbiology.

[10]  Madhukar Pai,et al.  Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis , 2011, PLoS medicine.

[11]  A. Van Deun,et al.  Duration of cough, TB suspects’ characteristics and service factors determine the yield of smear microscopy , 2010, Tropical medicine & international health : TM & IH.

[12]  P. Burney,et al.  Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB? , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  W. Venter,et al.  Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study , 2011, PLoS medicine.

[14]  S. Lawn,et al.  Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study , 2011, PLoS medicine.

[15]  A. Ramsay,et al.  Evidence-Based Tuberculosis Diagnosis , 2008, PLoS medicine.

[16]  K. Floyd,et al.  MDR tuberculosis--critical steps for prevention and control. , 2010, The New England journal of medicine.

[17]  Milton C Weinstein,et al.  Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis , 2006, PLoS medicine.

[18]  D. Enarson,et al.  The FIDELIS initiative: innovative strategies for increased case finding. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  K. Rasanathan,et al.  The social determinants of health: key to global tuberculosis control. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  P. Farmer,et al.  Programmatic management of multidrug-resistant tuberculosis: models from three countries. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  J. Creswell,et al.  Tuberculosis and poverty: what is being done. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  Stefan Niemann,et al.  Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance , 2006, PLoS medicine.

[23]  M. Behr,et al.  Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  L. Scott,et al.  Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? , 2010, Expert review of molecular diagnostics.

[25]  R. Upshur,et al.  Tuberculosis and poverty: what could (and should) be done? , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[26]  Philippe Glaziou,et al.  Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.

[27]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[28]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[29]  S. Lal,et al.  Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. , 2010, Indian journal of medical microbiology.

[30]  R. Centor,et al.  Clinical Prediction Rule for Stratifying Risk of Pulmonary Multidrug-Resistant Tuberculosis , 2010, PloS one.